Medical Devices

Medtech company raises funds to help eliminate MRSA nasal colonization

MoneyMed Dev Corp., a Delaware-based startup, has raised $775,000 from private investors to reduce hospital-acquired infections or surgical-site infections. Med Dev’s devices all attempt a non-antibiotic approach to eradicating nasal MRSA colonization, which is “the No. 1 predictor” for SSIs in orthopedic, cardiac and GI surgeries, according to Chairman Mike Martin.

The company still seeks $2,225,000.

He said the money will go toward  additional testing and expenses for U.S. Food and Drug Administration approval. He hopes to be selling product by Jan. 1, 2014. The company incorporated in 2012.

Martin said the company has commitments for the remaining $225,000 it sought, and Med Dev is now in its second round of mezzanine funding.

According to the regulatory filing, Med Dev’s officers include Martin, William Peters, Michael Moore and Thomas Finley.


We’re bringing active investors and corporate development execs together with promising startups at MedCity News INVEST. Join us April 12-13, 2016, in Chicago for the premier national investing conference based in the Midwest.

No comments